ENSC (Ensysce Biosciences Inc.) Aset Bersih Perusahaan

Ensysce Biosciences (ENSC) targets the safe pain management segment, where key trials are currently underway and strategic B2B partners are being sought. Business growth relies on MPAR technology and FDA approval of new opioids designed to combat addiction. The current metric stands at -0.00. Serving as a valuation tool, this price chart confirms the asset's macro resilience, as demand for pharmaceuticals remains independent of GDP phases.

For the biotechnology sector company Ensysce Biosciences (ENSC), which implements eco-friendly closed-loop production cycles, the scale of operations is determined by the volume of net assets minus liabilities. The dynamics of the book capitalization value reflect the real value of equity, allowing investors to assess the financial stability of Ensysce Biosciences against market shocks and the efficiency of resource utilization under strict ESG standards.